NEW YORK (GenomeWeb News) – Diagnostics developer Tethys Bioscience said today that it has bought Lipomics Technologies, a metabolite-profiling firm, for an undisclosed sum.
 
Tethys, which earlier this year began selling a test for diabetes risk, said the acquisition will help it to develop new tests to predict the likelihood of developing chronic diseases. Currently, Emeryville, Calif.-based Tethys is developing a test to predict the likelihood that a person will experience osteoporotic bone fracture or a major cardiac event.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.